Coverage
-
October 18, 2017
A Massachusetts federal judge renewed his criticism Wednesday for plea bargains that deprive courts of sentencing discretion, but stopped short of tossing out a $36 million deal that would preclude him from weighing in on the ramifications of Aegerion Pharmaceuticals Inc. admitting to fraud in connection with its expensive cholesterol drug.
1 other articles on this case.
View all »